Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor–Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance
MedComm · 2026-04 · 7 (4)
DOI: 10.1002/mco2.70676 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 05.04.2026. Verfasst von Shuang Geng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) College of Basic Medical Sciences Fudan University Shanghai China. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Major Research Plan, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chronic hepatitis B (CHB) remains incurable due to the immune system's tolerance toward the hepatitis B virus (HBV) surface antigen (HBsAg). This study aimed to achieve a functional cure by breaking HBV tolerance through immunotherapy. CHB patients were treated with either standard nucleotide analog (NA) therapy (Adefovir Dipivoxil, ADV) (Cohort 1) or ADV combined with interferon‐alpha (IFN‐α) (Cohort 2). Additionally, a third cohort received the THRIL‐GM‐Vac regimen: three low‐dose GM‐CSF injections followed by one dose of the HBV vaccine, alongside standard treatment. THRIL‐GM‐Vac treatment (Cohort 3) achieved a significant 2log10 reduction in HBsAg levels in 21.7% of participants, and 8.7% HBsAg clearance in Cohort 3 compared to 0% and 4.17% in Cohorts 1 and 2, respectively. Furthermore, THRIL‐GM‐Vac significantly reduced HBV‐specific tolerogenic T cells (Tregs), explaining the sustained HBsAg decrease. Upregulation of anti‐HBV T cell responses confirmed THRIL‐GM‐Vac's ability to disrupt HBV tolerance and enhance HBsAg‐specific cellular immunity. This suggests its potential effectiveness in treating individuals with moderate to low HBsAg levels. THRIL‐GM‐Vac treatment in Cohort 3 resulted in 8.7% HBsAg clearance alongside Treg depletion and enhanced anti‐viral T cell responses. These findings present a promising strategy to overcome immunotolerance and potentially combat chronic HBV infection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) College of Basic Medical Sciences Fudan University Shanghai China.
- Cumming School of Medicine University of Calgary Calgary Canada.
- Shanghai Institute of Infectious Disease and Biosecurity Fudan University Shanghai China.
- National Medical Center for Infectious Diseases Huashan Hospital Fudan University Shanghai China.
- Department of Infectious Disease the First Affiliated Hospital Zhejiang University Hangzhou Zhejiang Province China.
- Advaccine Biopharmaceutics (Suzhou) Co. LTD Suzhou Jiangsu Province China.
ORCID-Profile: Bin Wang
Förderung
- National Key Research and Development Program of China
- Major Research Plan
- National Natural Science Foundation of China
Zitieren
APA
Geng, S., Yang, F., Jia, H., Zhao, G., Zhao, W., Yu, J., Zhu, H., Cai, H., Yang, L., Zhang, S., Yu, F., Jin, X., Zhang, S., Wang, X., Yang, Y., Zhang, J., & Wang, B. (2026). Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor–Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance. MedComm, 7(4). https://doi.org/10.1002/mco2.70676
Vancouver
Geng S, Yang F, Jia H, Zhao G, Zhao W, Yu J, et al. Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor–Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance. MedComm. 2026;7(4). doi:10.1002/mco2.70676
BibTeX
@article{Geng2026,
author = {Geng, Shuang and Yang, Feifei and Jia, Hongyu and Zhao, Gan and Zhao, Weidong and Yu, Jie and Zhu, Haoxiang and Cai, Huan and Yang, Lishan and Zhang, Shuren and Yu, Fang and Jin, Xiang and Zhang, Shijie and Wang, Xianzheng and Yang, Yida and Zhang, Jiming and Wang, Bin},
title = {Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor–Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance},
journal = {MedComm},
year = {2026},
volume = {7},
number = {4},
doi = {10.1002/mco2.70676}
}
EUVIMED